Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

A-040

Supelco

Aminorex -Lösung

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C9H10N2O
CAS-Nummer:
2207-50-3
Molekulargewicht:
162.19
UNSPSC-Code:
41116107

Qualität

certified reference material

Form

liquid

Leistungsmerkmale

SNAP-N-SPIKE®. SNAP-N-SHOOT®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Konzentration

1.0 mg/mL in acetonitrile

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

forensics and toxicology
pharmaceutical (small molecule)

Format

single component solution

Lagertemp.

−20°C

SMILES String

NC1=NCC(O1)c2ccccc2

InChI

1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11)

InChIKey

SYAKTDIEAPMBAL-UHFFFAOYSA-N

Allgemeine Beschreibung

An analytical reference standard suitable for use in LC/MS or GC/MS methods for clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research applications. Aminorex is an anorectic stimulant drug and appetite suppressant marketed under the names Menocil and Apiquel®. The drug was retired from the market after it was found to cause pulmonary hypertension.

Rechtliche Hinweise

Apiquel is a registered trademark of Puricorp Holdings LLC
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

A-016

(±)-Amphetamin-d11 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

Amin-Mischung 6 -Lösung, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamin-d5 (Deuterium-Markierung am Ring) -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-Amphetamin-d5 (Deuterium-Markierung an der Seitenkette) -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(±)-Amphetamin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-008

S(+)-Amphetamin (Dextro-Amphetamin) -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-Amphetamin-d5 (Deuterium-Markierung an der Seitenkette) -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamin-d8 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamin-d8 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-Amphetamin-d11 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-Amphetamin-d6 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-Amphetamin-d6 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-Amphetamin (Levo-Amphetamin), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

Lisdexamfetamin-D4 Dimesylat -Lösung, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

M-093

(±)-Methamphetamine-D14 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA -hydrochlorid -Lösung, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

D-122

Diethylpropion-D10 hydrochloride solution, 100 μg/mL in methanol (with 1% 1 M HCl, (as free base)), certified reference material, ampule of 1 mL, Cerilliant®

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Elisabetta Bertol et al.
Journal of pharmaceutical and biomedical analysis, 55(5), 1186-1189 (2011-05-03)
The Drug Enforcement Administration (DEA) reports that as of October 2010, 79% of all cocaine seized in the United States contained levamisole. The equine conversion of levamisole to aminorex has been demonstrated. However, the metabolic fate of levamisole in humans
S P Gaine et al.
Chest, 118(5), 1496-1497 (2000-11-18)
Pulmonary hypertension has been associated with ingestion of the appetite suppressant aminorex. A similar compound, 4-methyl-aminorex (street names, "U-4-E-uh" [pronounced euphoria] or "ice"), is a "designer" drug with central stimulant activity. This drug was discovered on the property of three
Aminorex to fen/phen: an epidemic foretold.
A P Fishman
Circulation, 99(1), 156-161 (1999-01-13)
Richard B Rothman et al.
Annals of the New York Academy of Sciences, 965, 109-126 (2002-07-10)
Several lines of evidence support a dual-deficit model of stimulant withdrawal in which decreases in synaptic dopamine (DA) and serotonin (5-HT) contribute to withdrawal symptoms, drug craving, and relapse. According to the dual-deficit model, DA dysfunction during withdrawal underlies anhedonia
N Sato et al.
Nihon rinsho. Japanese journal of clinical medicine, 59(6), 1197-1202 (2001-06-20)
Primary pulmonary hypertension (PPH) is a rare, often fatal disease that tends to occur with particular frequency in woman. The factors leading to its development remain enigmatic. A variety of toxins and drugs have been implicated in the pathogenesis of
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.